Filing Flows › Nuvation Bio (NUVB) › Q3 2026
Nuvation Bio (NUVB) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Nuvation Bio (NUVB) reported revenue of $45.0M for the third quarter 2026 (Q3 2026), +243% from a year earlier and +42% from the quarter before. Operating margin was -93.9%, net loss $41.9M (93.2% of revenue).
Nuvation Bio, Q3 2026: revenue $45.0M (+243% year over year), operating margin -93.9%, net loss $41.9M, operating cash flow −$38.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $45.0M | +42% | +243% |
| Operating profit | −$42.2M | — | — |
| Net earnings | −$41.9M | — | — |
| Operating cash flow | −$38.6M | — | — |
What changed
Revenue was $45.0M in Q3 2026, up 243% year over year and up 42% from the previous quarter. Product Revenue was the largest line at 61% of revenue. Product Revenue added $19.8M year over year (up 257%), 62% of the total change.
Operating costs exceeded revenue by $42.2M, an operating margin of -93.9%. The fastest-growing cost line was SG&A (+14%). The quarter ended with a net loss of $41.9M, narrower than the previous quarter's $62.8M loss.
Operating cash flow was −$38.6M. Non-cash charges added back $578K of depreciation and amortization and $10.1M of share-based compensation. Working capital and other items used $7.3M.
Questions
What was Nuvation Bio's revenue in the third quarter 2026?
Nuvation Bio (NUVB) reported revenue of $45.0M for the third quarter 2026 (Q3 2026), +243% from a year earlier and +42% from the quarter before.
Was Nuvation Bio profitable in the third quarter 2026?
Operating loss was $42.2M (-93.9% of revenue) and net loss $41.9M.
Source: Nuvation Bio 10-Q on SEC EDGAR.